Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Rodney Myers

Neurology Tulsa, OK Medical Doctor

NPI 1740211044 CMS profile 260121

1245 S Utica Ave, Tulsa, OK 74104

Open in the dashboard

General payments

$6,160

410 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Rodney Myers of Tulsa, OK is reported in the CMS Open Payments database as having received $6,160 across 410 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $2,190 131
2020 General $1,126 78
2019 General $2,844 201

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodney Myers
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Rodney Myers were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Rodney Myers Neurology median Middle half National median
2019 $2,844 $474 $118–$2,177 $163
2020 $1,126 $367 $82–$2,309 $114
2021 $2,190 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Biogen, Inc. $580 22 payments
  2. Amgen Inc. $566 38 payments
  3. Teva Pharmaceuticals USA, Inc. $465 20 payments
  4. EMD Serono, Inc. $448 24 payments
  5. UCB, Inc. $438 27 payments
  6. CSL Behring $383 22 payments
  7. Allergan Inc. $372 37 payments
  8. Lundbeck LLC $366 17 payments
  9. Novartis Pharmaceuticals Corporation $281 18 payments
  10. AbbVie, Inc. $274 40 payments
  11. Other $1,985 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $6,123 407 payments
  2. Education $22 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15 1 payment
Products named General payments · program years 2019–2021
  1. AIMOVIG $679 45 payments
  2. Ajovy $413 15 payments
  3. Hizentra $383 22 payments
  4. VYEPTI $366 17 payments
  5. TYSABRI $354 14 payments
  6. UBRELVY Neuroscience $294 32 payments
  7. Briviact $263 15 payments
  8. UBRELVY Neuroscience $230 33 payments
  9. VNS - Sentiva $228 7 payments
  10. Mavenclad $222 16 payments
  11. Other $2,709 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

410 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record